| For: | Jeng KS, Sheen IS, Wang YC, Gu SL, Chu CM, Shih SC, Wang PC, Chang WH, Wang HY. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: A prospective study. World J Gastroenterol 2004; 10(5): 643-648 [PMID: 14991930 DOI: 10.3748/wjg.v10.i5.643] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v10/i5/643.htm |
| Number | Citing Articles |
| 1 |
Andrew X Zhu. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. Expert Opinion on Investigational Drugs 2010; 19(5) doi: 10.1517/13543781003767426
|
| 2 |
Dattatrya Shetti, Venkata Ramana Mallela, Wenjing Ye, Mahyar Sharif, Filip Ambrozkiewicz, Andriy Trailin, Václav Liška, Kari Hemminki. Emerging role of circulating cell-free RNA as a non-invasive biomarker for hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2024; 200 doi: 10.1016/j.critrevonc.2024.104391
|
| 3 |
SANG YOUN HWANG, KYU HEO, JOON SEOK KIM, JUNG WOO IM, SUN MI LEE, MONG CHO, DAE HWAN KANG, JEONG HEO, JUN WOO LEE, CHEOL WON CHOI, KWANGMO YANG. Emodin attenuates radioresistance induced by hypoxia in HepG2 cells via the enhancement of PARP1 cleavage and inhibition of JMJD2B. Oncology Reports 2015; 33(4) doi: 10.3892/or.2015.3744
|
| 4 |
|
| 5 |
Andrew X. Zhu. Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?. The Oncologist 2006; 11(7) doi: 10.1634/theoncologist.11-7-790
|
| 6 |
Ismail Labgaa, Augusto Villanueva, Olivier Dormond, Nicolas Demartines, Emmanuel Melloul. The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. Cancers 2021; 13(4) doi: 10.3390/cancers13040659
|
| 7 |
Koji Miyahara, Kazuhiro Nouso, Takeshi Tomoda, Sayo Kobayashi, Hiroaki Hagihara, Kenji Kuwaki, Junichi Toshimori, Hideki Onishi, Fusao Ikeda, Yasuhiro Miyake, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Kazuhide Yamamoto. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2011; 26(11) doi: 10.1111/j.1440-1746.2011.06887.x
|
| 8 |
Andrew X. Zhu. Molecularly Targeted Therapy for Advanced Hepatocellular Carcinoma in 2012: Current Status and Future Perspectives. Seminars in Oncology 2012; 39(4) doi: 10.1053/j.seminoncol.2012.05.014
|
| 9 |
Po‐Lin Tseng, Ming‐Hong Tai, Chao‐Cheng Huang, Chih‐Chi Wang, Jui‐Wei Lin, Chao‐Hung Hung, Chien‐Hung Chen, Jing‐Houng Wang, Sheng‐Nan Lu, Chuan‐Mo Lee, Chi‐Sin Changchien, Tsung‐Hui Hu. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. Journal of Surgical Oncology 2008; 98(5) doi: 10.1002/jso.21109
|
| 10 |
Andrew X. Zhu, Nagaraj S. Holalkere, Alona Muzikansky, Kerry Horgan, Dushyant V. Sahani. Early Antiangiogenic Activity of Bevacizumab Evaluated by Computed Tomography Perfusion Scan in Patients with Advanced Hepatocellular Carcinoma. The Oncologist 2008; 13(2) doi: 10.1634/theoncologist.2007-0174
|
| 11 |
Lorenzo Fornaro, Caterina Vivaldi, Chiara Caparello, Rodolfo Sacco, Virginia Rotella, Gianna Musettini, Sauro Luchi, Edi Editta Baldini, Alfredo Falcone, Gianluca Masi. Dissecting Signaling Pathways in Hepatocellular Carcinoma: New Perspectives in Medical Therapy. Future Oncology 2014; 10(2) doi: 10.2217/fon.13.181
|
| 12 |
Antoine Hollebecque, David Malka, Charles Ferté, Michel Ducreux, Valérie Boige. Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons. European Journal of Cancer 2015; 51(3) doi: 10.1016/j.ejca.2014.12.005
|
| 13 |
Anuradha Budhu, Junfang Ji, Xin Wei Wang. Hepatocellular Carcinoma. 2009; doi: 10.1007/978-1-60327-376-3_5
|
| 14 |
Richard S. Finn. Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?. Clinical Cancer Research 2010; 16(2) doi: 10.1158/1078-0432.CCR-09-2084
|
| 15 |
Benyamin Lukito, Ivet Suriapranata, Pendrianto Pendrianto, Ali Sulaiman, Irawan Yusuf, FX Budhianto Suhadi, George Mathew, Ferry Sandra. Vascular Endothelial Growth Factor Level as A Predictor of Hepatocellular Carcinoma in Liver Cirrhosis Patients. The Indonesian Biomedical Journal 2014; 6(3) doi: 10.18585/inabj.v6i3.30
|
| 16 |
Chace Wilson, Nicholas W. Dias, Stefania Pancini, Vitor Mercadante, Fernando H. Biase. Delayed processing of blood samples impairs the accuracy of mRNA-based biomarkers. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-12178-5
|
| 17 |
Brian I. Carr. Hepatocellular carcinoma: Current management and future trends. Gastroenterology 2004; 127(5) doi: 10.1053/j.gastro.2004.09.036
|
| 18 |
Perumal Vivekanandan, Om V Singh. High-dimensional biology to comprehend hepatocellular carcinoma. Expert Review of Proteomics 2008; 5(1) doi: 10.1586/14789450.5.1.45
|
| 19 |
Christopher D. Mann, Christopher P. Neal, Giuseppe Garcea, Margaret M. Manson, Ashley R. Dennison, David P. Berry. Prognostic molecular markers in hepatocellular carcinoma: A systematic review. European Journal of Cancer 2007; 43(6) doi: 10.1016/j.ejca.2007.01.004
|
| 20 |
Geertu Deli, Can-Hao Jin, Rong Mu, Song Yang, Yue Liang, De Chen, Masatoshi Makuuchi. Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World Journal of Gastroenterology 2005; 11(7): 960-963 doi: 10.3748/wjg.v11.i7.960
|
| 21 |
Malin Sund, Michael Zeisberg, Raghu Kalluri. Endogenous Stimulators and Inhibitors of Angiogenesis in Gastrointestinal Cancers: Basic Science to Clinical Application. Gastroenterology 2005; 129(6) doi: 10.1053/j.gastro.2005.06.023
|
| 22 |
Matthias Pinter, Wolfgang Sieghart, Monika Schmid, Bernhard Dauser, Gerald Prager, Hans Peter Dienes, Michael Trauner, Markus Peck‐Radosavljevic. Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF‐A expression in hepatocellular carcinoma. United European Gastroenterology Journal 2013; 1(4) doi: 10.1177/2050640613496605
|
| 23 |
Kimberly Terry, Mehmet Sitki Copur. Molecular Targeted Therapy of Hepatocellular Carcinoma. Journal of Cancer Therapy 2013; 4(02) doi: 10.4236/jct.2013.42A052
|
| 24 |
Su Jin Lee, Ho Yeong Lim. Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists. Expert Opinion on Emerging Drugs 2017; 22(2) doi: 10.1080/14728214.2017.1330886
|
| 25 |
Matthias Preusser, Stefan Wolfsberger, Christine Haberler, Helene Breitschopf, Thomas Czech, Irene Slavc, Adrian L. Harris, Till Acker, Herbert Budka, Johannes A. Hainfellner. Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathologica 2005; 109(2) doi: 10.1007/s00401-004-0938-8
|
| 26 |
Andrew X. Zhu. Systemic Treatment of Hepatocellular Carcinoma: Dawn of a New Era?. Annals of Surgical Oncology 2010; 17(5) doi: 10.1245/s10434-010-0975-6
|
| 27 |
Jun Muto, Ken Shirabe, Keishi Sugimachi, Yoshihiko Maehara. Review of angiogenesis in hepatocellular carcinoma. Hepatology Research 2015; 45(1) doi: 10.1111/hepr.12310
|
| 28 |
Roberta Pang, Ronnie T.P. Poon. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Letters 2006; 242(2) doi: 10.1016/j.canlet.2006.01.008
|
| 29 |
Kun‐Chun Chiang, Chun‐Nan Yeh, Miin‐Fu Chen, Tai C Chen. Hepatocellular carcinoma and vitamin D: A review. Journal of Gastroenterology and Hepatology 2011; 26(11) doi: 10.1111/j.1440-1746.2011.06892.x
|
| 30 |
Ahmed O. Kaseb, Amr Hanbali, Matthew Cotant, Manal M. Hassan, Ira Wollner, Philip A. Philip. Vascular endothelial growth factor in the management of hepatocellular carcinoma. Cancer 2009; 115(21) doi: 10.1002/cncr.24537
|
| 31 |
SHANSHAN SHI, CHENXING YUAN, KAIZAN ZHUANG, GUIKAI LIANG, ZHANGTING YAO, DUODUO WANG, QINJIE WENG, JI CAO, PEIHUA LUO, HONG ZHU, LING DING, SHENGLIN MA. Resistance of SMMC-7721 hepatoma cells to etoposide in hypoxia is reversed by VEGF inhibitor. Molecular Medicine Reports 2015; 11(5) doi: 10.3892/mmr.2015.3217
|
| 32 |
F. Meriggi, A. Zaniboni. Gemox: A Widely Useful Therapy Against Solid Tumors-Review and Personal Experience. Journal of Chemotherapy 2010; 22(5) doi: 10.1179/joc.2010.22.5.298
|
| 33 |
Karen Mulder, Sheryl Koski, Andrew Scarfe, Quincy Chu, Karen King, Jennifer Spratlin. Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget 2010; 1(7) doi: 10.18632/oncotarget.187
|
| 34 |
D. Germano, V. Tinessa, E. Barletta, L. Cannella, B. Daniele. Targeted Therapy for Advanced Hepatocellular Cancer in the Elderly: Focus on Sorafenib. Drugs & Aging 2013; 30(11) doi: 10.1007/s40266-013-0124-6
|
| 35 |
Andrew X. Zhu. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2008; 112(2) doi: 10.1002/cncr.23175
|
| 36 |
S J Schoenleber, D M Kurtz, J A Talwalkar, L R Roberts, G J Gores. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. British Journal of Cancer 2009; 100(9) doi: 10.1038/sj.bjc.6605017
|
| 37 |
S.-Y. Gao, L. Tang, Y. Cui, X.-T. Li, X.-Y. Zhang, J. Shan, Y.-S. Sun, X.-P. Zhang. Tumor angiogenesis-related parameters in multi-phase enhanced CT correlated with outcomes of hepatocellular carcinoma patients after radical hepatectomy. European Journal of Surgical Oncology (EJSO) 2016; 42(4) doi: 10.1016/j.ejso.2016.01.008
|
| 38 |
Satoshi Miuma, Tatsuki Ichikawa, Kazuhiko Arima, Shigeyuki Takeshita, Toru Muraoka, Toshihisa Matsuzaki, Masashi Ootani, Hidetaka Shibata, Motohisa Akiyama, Eisuke Ozawa, Hisamitsu Miyaaki, Naota Taura, Fuminao Takeshima, Kazuhiko Nakao. Branched‐chain amino acid deficiency stabilizes insulin‐induced vascular endothelial growth factor mRNA in hepatocellular carcinoma cells. Journal of Cellular Biochemistry 2012; 113(10) doi: 10.1002/jcb.24188
|
| 39 |
Eleni Liapi, Christos S. Georgiades, Kelvin Hong, Jean-Francois H. Geschwind. Interventional Oncology. 2008; doi: 10.1017/CBO9780511722226.018
|
| 40 |
Andrew X. Zhu, Dan G. Duda, Dushyant V. Sahani, Rakesh K. Jain. HCC and angiogenesis: possible targets and future directions. Nature Reviews Clinical Oncology 2011; 8(5) doi: 10.1038/nrclinonc.2011.30
|
| 41 |
Andrew X. Zhu. New agents on the horizon in hepatocellular carcinoma. Therapeutic Advances in Medical Oncology 2013; 5(1) doi: 10.1177/1758834012458480
|
| 42 |
Andrew X. Zhu, Lawrence S. Blaszkowsky, David P. Ryan, Jeffrey W. Clark, Alona Muzikansky, Kerry Horgan, Susan Sheehan, Kelly E. Hale, Peter C. Enzinger, Pankaj Bhargava, Keith Stuart. Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology 2006; 24(12) doi: 10.1200/JCO.2005.04.9130
|
| 43 |
Andrew X Zhu. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?. Expert Review of Anticancer Therapy 2008; 8(4) doi: 10.1586/14737140.8.4.499
|
| 44 |
ZHONG-LIN ZHANG, JI-FA ZHANG, YU-FENG YUAN, YUE-MING HE, QUAN-YAN LIU, XIAO-WEN MAO, YONG-BIAO AI, ZHI-SU LIU. Suppression of angiogenesis and tumor growth in vitro and in vivo using an anti-angiopoietin-2 single-chain antibody. Experimental and Therapeutic Medicine 2014; 7(3) doi: 10.3892/etm.2014.1476
|
| 45 |
Faris Alrumaihi. Role of Liquid Biopsy for Early Detection, Prognosis, and Therapeutic Monitoring of Hepatocellular Carcinoma. Diagnostics 2025; 15(13) doi: 10.3390/diagnostics15131655
|
| 46 |
J. Stuart Salmon, A. Craig Lockhart, Jordan Berlin. Anti-Angiogenic Treatment of Gastrointestinal Malignancies. Cancer Investigation 2005; 23(8) doi: 10.1080/07357900500360024
|
| 47 |
Ming‐Yen Hsieh, Zu‐Yau Lin, Wan‐Long Chuang. Serial serum VEGF‐A, angiopoietin‐2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization. The Kaohsiung Journal of Medical Sciences 2011; 27(8) doi: 10.1016/j.kjms.2011.03.008
|
| 48 |
Kuo-Shyang Jeng, Chi-Juei Jeng, Wen-Juei Jeng, I-Shyan Sheen, Shih-Yun Li, Ssu-Jung Lu, Chiung-Fang Chang. Tropism of liver epithelial cells toward hepatocellular carcinoma in vitro and in vivo with altering gene expression of cancer stem cells. The American Journal of Surgery 2018; 215(4) doi: 10.1016/j.amjsurg.2017.11.041
|
| 49 |
Andrew X. Zhu, Charles S. Fuchs, Jeffrey W. Clark, Alona Muzikansky, Kerry Taylor, Susan Sheehan, Kayao Tam, Elizabeth Yung, Matthew H. Kulke, David P. Ryan. A Phase II Study of Epirubicin and Thalidomide in Unresectable or Metastatic Hepatocellular Carcinoma. The Oncologist 2005; 10(6) doi: 10.1634/theoncologist.10-6-392
|
| 50 |
Richard S Finn, Andrew X Zhu. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Review of Anticancer Therapy 2009; 9(4) doi: 10.1586/era.09.6
|